Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Whitehawk Therapeutics, Inc. (WHWK : NSDQ)

• Company Description    Aadi Bioscience Inc. is a clinical-stage biopharmaceutical company. It focuses on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes. Aadi Bioscience Inc., formerly known as Aerpio Pharmaceuticals Inc., is based in LOS ANGELES. Number of Employees: 23

• Price / Volume Information    Yesterday's Closing Price: $3.71 Daily Weekly Monthly 20 Day Moving Average: 639,366 shares Shares Outstanding: 49.45 (millions) Market Capitalization: $183.47 (millions) Beta: 0.77 52 Week High: $5.50 52 Week Low: $1.57 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -9.73% -10.40% 12 Week -7.48% -10.01% Year To Date 53.31% 46.24%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2 HEADQUARTERS PLAZA EAST BUILDING 11TH FLOOR - MORRISTOWN,NJ 7960 USA ph: 551-321-2234 fax: - ir@whitehawktx.com https://ir.whitehawktx.com

• General Corporate Information    Officers David J. Lennon - Chief Executive Officer and President and Director Caley Castelein - Chairman Scott Giacobello - Chief Financial Officer Behzad Aghazadeh - Director Anupam Dalal - Director Peer Information Whitehawk Therapeutics, Inc. (CORR.) Whitehawk Therapeutics, Inc. (RSPI) Whitehawk Therapeutics, Inc. (CGXP) Whitehawk Therapeutics, Inc. (BGEN) Whitehawk Therapeutics, Inc. (GTBP) Whitehawk Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00032Q104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/06/26 Share - Related Items Shares Outstanding: 49.45 Most Recent Split Date: 8.00 (0.07:1) Beta: 0.77 Market Capitalization: $183.47 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.34 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.37 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.58 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 11.11% vs. Previous Quarter: 5.88% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - - 03/31/26 - -79.63 12/31/25 - -62.88 ROA 06/30/26 - - 03/31/26 - -74.01 12/31/25 - -58.98 Current Ratio 06/30/26 - - 03/31/26 - 11.36 12/31/25 - 10.26 Quick Ratio 06/30/26 - - 03/31/26 - 11.36 12/31/25 - 10.26 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - -288.26 Book Value 06/30/26 - - 03/31/26 - 2.35 12/31/25 - 2.89 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©